Deal facts
- Buyer
- BioAdaptives, Inc.
- Target
- Xycota Biosciences LLC
- Deal value
- Not disclosed
- Announced
- 4 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares
Sources
BioAdaptives, Inc. entered into a definitive Membership Interest Purchase Agreement on October 29, 2026 to acquire 100% of the issued and outstanding membership interests of Xycota Biosciences LLC, a Wyoming limited liability company. At closing Xycota would become a wholly owned subsidiary. The other parties include Xycota's members, co-founders Brad Listermann and Marvin S. Hausman, M.D., and the investors Monroe Street Capital Partners LP and Lambda Ventures LLC. BioAdaptives reported that it issued a press release on November 4, 2026 announcing the execution of the agreement.
Xycota is a preclinical biotechnology company developing central-nervous-system candidates. They include a sub-perceptual oral psilocybin candidate being prepared for a planned Phase 1/2 study in mild PTSD in Canada, and an exosome-formulated psilocin candidate for frontotemporal dementia, for which an Orphan Drug Designation request is on file with the FDA but has not been granted. Xycota also has early preclinical research in traumatic brain injury. The filing states that Xycota is not a party to any clinical trial in which a subject has been dosed and that none of its candidates has received regulatory approval.
The consideration is paid in stock, not cash. The filing states that no cash purchase price is payable and that no securities have been issued yet. Within 20 business days after closing, BioAdaptives must issue the founders a new series of convertible preferred stock sized to represent 40% of the company's total voting power and economic ownership. On the agreement's illustrative figures, that is about 261 million common-equivalent shares against a denominator of roughly 391.3 million. BioAdaptives CEO James E. Keener is also to receive non-convertible voting preferred carrying 51% of voting power. It transfers to the founders on the earliest of a defined Control Event (such as a written FDA Orphan Drug Designation grant for a Xycota candidate in FTD), a spin-off of the nutraceutical business, or a final regulatory denial determined under the agreement to have been caused by the company.
The investors have agreed to fund $150,000 in four tranches against 12-month convertible promissory notes, with a 36-month right to buy up to $800,000 of additional notes. Of that, $400,000 is callable on a Control Event, subject to the company satisfying Rule 144 issuer conditions; that funding obligation ends if those conditions are not satisfied within 12 months. The other $400,000 is optional. Closing requires approval by the BioAdaptives board and Xycota's members, among other conditions, and is not conditioned on issuing the new preferred stock. The agreement terminates automatically if closing has not occurred by June 30, 2027. BioAdaptives intends to file another Form 8-K on closing.
Deal timeline
1 update- Firm intention
BioAdaptives, Inc. firm intention to acquire Xycota Biosciences LLC
Item 1.01 Entry into a Material Definitive Agreement. Overview of the Membership Interest Purchase Agreement On October 29, 2026, BioAdaptives, Inc., a Delaware corporation (the “Company” or “Parent”), entered into a definitive Membership Interest Purchase Agreement (the “Agreement”) with Xycota Biosciences LLC, a Wyoming limited liability company (“Xycota”), the members of Xycota, Xycota Co-Found
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
BioAdaptives, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive